Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fingolimod for Chemotherapy-Induced Peripheral Neuropathy
NCT03943498Phase 1Completed
- Sponsor
- Mayo Clinic
- Start
- May 2019
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of fingolimod in chemotherapy-induced peripheral neuropathy (CIPN), sponsored by Mayo Clinic. Started May 2019; status: completed.
02
Drugs
fingolimod
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT03943498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03943498.